December 19, 2017 Sophia Vida
Biotech & Pharma

The FDA Has Approved Spark Therapeutics’ Luxturna Therapy

In what is the first in the field of gene therapy, Spark Therapeutics’ Luxturna has been granted Food and Drug Administration (FDA) approval. Shares of the stock quickly soaed almost 7% before retracing and closing down 0.2% on Tuesday. According to FDA Commissioner Scott Gottlieb, the approval marks another first in gene therapy. The approval … Continue reading “The FDA Has Approved Spark Therapeutics’ Luxturna Therapy”